Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2020-08-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Guangfa Securities regarding the postponement of investment projects funded by raised capital by Yantai Zhenghai Biotechnology Co., Ltd. It includes specifics about the capital raised, usage, project delays, reasons for delays, and approvals by the board, supervisory committee, and independent directors. The document is not a full financial report but a regulatory compliance and verification report related to capital investment project delays. It does not contain financial statements or earnings data but focuses on the status and management of raised funds and project timelines. This fits the category of a Capital/Financing Update (CAP), as it updates on the use and management of raised capital and project investment timelines.
2020-08-04 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, qualifications, nomination, election, rights, and obligations of independent directors at the company. It references relevant laws and regulations such as the Company Law and Securities Law of China, and the company's Articles of Association. The content is a governance document outlining internal rules and practices related to board structure and director duties. There is no financial data, no audit or financial report, no announcement of voting results, no earnings or capital update, and no legal proceeding information. This fits the definition of a Governance Information report (CGR), which details the company's internal rules, board structure, and governance practices.
2020-08-04 Chinese
关于召开2020年第一次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice for convening the 2020 first extraordinary general meeting of shareholders of Yantai Zhenghai Biotechnology Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, registration methods, and attachments such as proxy forms and shareholder registration forms. The document does not contain financial statements or results but is clearly a formal notification to shareholders about the meeting and the matters to be discussed and voted on. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is over 6,000 characters and contains substantive meeting details, not just a brief announcement or a report publication notice. Therefore, the correct classification is AGM Information (AGM-R).
2020-08-04 Chinese
2020年半年度报告及摘要披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (502 characters) indicating that the company's 2020 half-year (semi-annual) report and its summary have been approved and published on an official disclosure website. It does not contain the actual financial data or detailed report content but rather informs investors where to find the full report. According to the 'Menu vs Meal' rule, such a brief notice about the report's availability is classified as a Report Publication Announcement (RPA), not the Interim Report (IR) itself.
2020-08-04 Chinese
广发证券股份有限公司关于公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor (广发证券股份有限公司) regarding the use of idle raised funds and own funds by 烟台正海生物科技股份有限公司 for cash management. It includes background on the raised funds, usage, approvals by the board, supervisory board, and independent directors, as well as the sponsor's verification opinion. The document is not a financial report itself but a verification or audit opinion related to the use of funds. It does not contain comprehensive financial statements or quarterly/yearly financial data. It is a standalone audit/verification report on a specific financial management matter, fitting the definition of an Audit Report / Information (AR). The document length is about 5207 characters, which is sufficient to be a full report rather than a mere announcement. Therefore, the appropriate classification is AR with high confidence. H1 2020
2020-08-04 Chinese
广发证券股份有限公司关于公司2020年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2020 Half-Year Follow-up Report' by a sponsoring securities company regarding a specific company. It contains detailed sections on sponsorship work overview, issues found and measures taken, company and shareholder commitments, and other matters related to the half-year period. The content includes substantive information about company governance, compliance, and financial oversight during the half-year period. The document length is 2508 characters, which is relatively short but contains detailed substantive content rather than just an announcement or certification. The document is not a full annual report but a mid-year report with detailed analysis and oversight information. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains substantive financial and operational data and analysis. H1 2020
2020-08-04 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.